Association for Molecular Pathology

Last updated
Association for Molecular Pathology
AbbreviationAMP
Formation1995;28 years ago (1995)
Type Nonprofit
Legal status 501(c)(3)
Headquarters Rockville, Maryland
Fields Molecular diagnostics
Membership
Approximately 2,800
President
Maria E. Arcilla, MD
Website www.amp.org

The Association for Molecular Pathology (abbreviated AMP) is a professional association of individuals serving patients through molecular diagnostics testing. Founded in 1995, the Association has more than 2,800 members in over 50 countries. [1]

Contents

Molecular diagnostics is one of the fastest growing fields of health care. Molecular genetic testing provides patients and their doctors with accurate diagnosis of a broad range of cancers, infectious diseases, and inherited conditions. By identifying the exact molecular genetic alterations or biomarkers in a patient’s specimen, molecular genetic testing can identify treatment targets for personalized precision medicine that have improved outcomes for many patients.

AMP is a volunteer-driven organization that concentrates on providing educational opportunities [2] to practitioners and the broader medical community, advocating for the profession and the molecular professional, and advancing clinical care through the publication of evidence-based practice guidelines. [3] AMP members work in academic and community medical centers, private and public health laboratories, government agencies, and the diagnostic manufacturing industry. Its membership includes pathologists, clinical laboratory scientists, technologists, trainees (who receive free membership while in training), clinicians and other health care personnel, government employees involved in regulatory oversight, and individuals in the in vitro diagnostics and pharmaceutical industries.  

AMP members are actively involved in volunteer committees, [4] scientific subdivisions, [5] and working groups to advance the field of molecular diagnostics.

Mission

The Association for Molecular Pathology is a 501(c)(3) non-profit scientific society that advances the clinical practice, science, and excellence of molecular and genomic laboratory medicine through education, innovation, and advocacy to enable the highest quality health care.

History

AMP was formed in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. The motivation for forming AMP came from numerous discussions and workshops that took place in the late 1980s and early 1990s. As new molecular technologies and applications emerged, questions about their use, standardization, licensing and accreditation, as well as medical training created consensus for a professional focus. At a workshop in November 1993, participants formed working groups that later became the Association’s initial four subdivisions: Hematopathology, Solid Tumors, Genetics, and Infectious Diseases. In 2012, Informatics was added as a fifth concentration, reflecting the new challenges and opportunities that Big Data management and interpretation has brought to the molecular field.  

Clinical Practice & Patient Care

AMP publishes evidence-based guidelines and freely available reports to provide best practices and recommendations, and to highlight the developments and changing practices in its rapidly evolving field. AMP frequently collaborates with other well-respected professional organizations, such as the College of American Pathologists (CAP), American Society of Clinical Oncology (ASCO), American College of Obstetricians and Gynecologists (ACOG) and American College of Medical Genetics and Genomics (ACMG) to share expertise and broaden the reach of various publications. Guidelines [3] are authored by AMP members elected to the Clinical Practice Committee or appointed by the Board of Directors as subject matter experts to specific working groups.

Education

AMP develops a wide range of educational resources, available in to bring understanding of new and evolving molecular testing techniques to members and other medical professionals. The Association hosts its annual meeting every November in North America, and an international meeting in the spring or summer. [6] AMP organizes educational webinars throughout the year as well as review courses and certificate programs for individuals seeking in-depth knowledge of molecular topics. [2] AMP also outreaches to patients with an education webpage, Molecular Medicine for Patients, [7] focused on molecular testing and its impact on human health. These educational resources for patients are available in both English and Spanish.

Advocacy

AMP advocates for molecular professionals and the patients they serve. In the U.S. molecular genetics testing is governed by a wide range of regulations, including the Clinical Laboratory Improvement Act (CLIA), the Centers for Medicare and Medicaid, and the Food and Drug Administration, that impact the performance and reimbursement of medical laboratory services. Through its advocacy efforts, such as the AMP Economics Summit, AMP strives to modernize the regulatory environment. It works to inform the U.S. Congress and federal agencies regarding public policy issues affecting molecular pathology. AMP seeks to shape and promote policies that ensure broad and equitable patient access to appropriate laboratory testing. Internationally, AMP members are involved in advocating for appropriate molecular diagnostic testing in several countries around the world. [8]


Association for Molecular Pathology v. Myriad Genetics, Inc.

AMP was the lead plaintiff in a landmark lawsuit challenging gene patents. As described by Executive Director Mary Williams, “gene patents created an intractable challenge for medical professionals and presented a potential barrier to entry for new technologies. In order for the field to advance, the courts needed to weigh in.” [9] In June 2013, the U.S. Supreme Court unanimously ruled, “A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring.” [10] On the fifth anniversary of the ruling, AMP released a video providing some of the background about AMP's decision to join the case and its journey to the Supreme Court. [11]

Publications

AMP co-owns The Journal of Molecular Diagnostics (JMD) with the American Society for Investigative Pathology.  First published in 1999, JMD is the highest ranked journal in its field, with an Impact Factor rating of 5.341 in 2021. [12] Its focus includes original research on advances in molecular diagnostic medicine in oncology, infectious diseases, hematopathology, inherited diseases, clinical informatics, as well as review articles. AMP members receive complementary online access to the journal with their membership, discounts on publication fees, and AMP makes its practice guidelines available free of charge. In addition, AMP working groups also collaborate with colleagues from other scholarly societies on reports appearing in publications other than JMD. [13]

Partnerships

AMP receives financial support from and collaborates with corporate sponsors to support the annual meeting and various other educational offerings. [14]

Related Research Articles

<span class="mw-page-title-main">Pathology</span> Study of the causes and effects of disease or injury, and how they arise

Pathology is the study of disease and injury. The word pathology also refers to the study of disease in general, incorporating a wide range of biology research fields and medical practices. However, when used in the context of modern medical treatment, the term is often used in a narrower fashion to refer to processes and tests that fall within the contemporary medical field of "general pathology", an area that includes a number of distinct but inter-related medical specialties that diagnose disease, mostly through analysis of tissue and human cell samples. Idiomatically, "a pathology" may also refer to the predicted or actual progression of particular diseases, and the affix pathy is sometimes used to indicate a state of disease in cases of both physical ailment and psychological conditions. A physician practicing pathology is called a pathologist.

<span class="mw-page-title-main">Anatomical pathology</span> Medical specialty

Anatomical pathology (Commonwealth) or anatomic pathology (U.S.) is a medical specialty that is concerned with the diagnosis of disease based on the macroscopic, microscopic, biochemical, immunologic and molecular examination of organs and tissues. Over the 20th century, surgical pathology has evolved tremendously: from historical examination of whole bodies (autopsy) to a more modernized practice, centered on the diagnosis and prognosis of cancer to guide treatment decision-making in oncology. Its modern founder was the Italian scientist Giovan Battista Morgagni from Forlì.

<span class="mw-page-title-main">Clinical chemistry</span> Area of clinical pathology that is generally concerned with analysis of bodily fluids

Clinical chemistry is a division in medical laboratory sciences focusing on qualitative tests of important compounds, referred to as analytes or markers, in bodily fluids and tissues using analytical techniques and specialized instruments. This interdisciplinary field includes knowledge from medicine, biology, chemistry, biomedical engineering, informatics, and an applied form of biochemistry.

Transfusion medicine is the branch of medicine that encompasses all aspects of the transfusion of blood and blood components including aspects related to hemovigilance. It includes issues of blood donation, immunohematology and other laboratory testing for transfusion-transmitted diseases, management and monitoring of clinical transfusion practices, patient blood management, therapeutic apheresis, stem cell collections, cellular therapy, and coagulation. Laboratory management and understanding of state and federal regulations related to blood products are also a large part of the field.

As with all utility patents in the United States, a biological patent provides the patent holder with the right to exclude others from making, using, selling, or importing the claimed invention or discovery in biology for a limited period of time - for patents filed after 1998, 20 years from the filing date.

A medical specialty is a branch of medical practice that is focused on a defined group of patients, diseases, skills, or philosophy. Examples include those branches of medicine that deal exclusively with children (paediatrics), cancer (oncology), laboratory medicine (pathology), or primary care. After completing medical school or other basic training, physicians or surgeons and other clinicians usually further their medical education in a specific specialty of medicine by completing a multiple-year residency to become a specialist.

The Royal College of Pathologists (RCPath) is a professional membership organisation. Its main function is the overseeing of postgraduate training, and its Fellowship Examination (FRCPath) is recognised as the standard assessment of fitness to practise in this branch of medicine.

<span class="mw-page-title-main">Clinical pathology</span> Medical specialty

Clinical pathology is a medical specialty that is concerned with the diagnosis of disease based on the laboratory analysis of bodily fluids, such as blood, urine, and tissue homogenates or extracts using the tools of chemistry, microbiology, hematology, molecular pathology, and Immunohaematology. This specialty requires a medical residency.

<span class="mw-page-title-main">Medical laboratory scientist</span> Medical professional who works in the laboratory

A medical laboratory scientist (MLS) or clinical laboratory scientist (CLS) or medical technologist (MT) performs diagnostic testing of blood and body fluids in clinical laboratories. The scope of a medical laboratory scientist's work begins with the receipt of patient or client specimens and terminates with the delivery of test results to physicians and other healthcare providers. The utility of clinical diagnostic testing relies squarely on the validity of test methodology. To this end, much of the work done by medical laboratory scientists involves ensuring specimen quality, interpreting test results, data-logging, testing control products, performing calibration, maintenance, validation, and troubleshooting of instrumentation as well as performing statistical analyses to verify the accuracy and repeatability of testing. Medical laboratory scientists may also assist healthcare providers with test selection and specimen collection and are responsible for prompt verbal delivery of critical lab results. Medical Laboratory Scientists in healthcare settings also play an important role in clinical diagnosis. An estimated 70% of medical decisions are based on laboratory test results and MLS contributions affect 95% of a health system's costs.

The American College of Medical Genetics and Genomics (ACMG) is an organization composed of biochemical, clinical, cytogenetic, medical and molecular geneticists, genetic counselors and other health care professionals committed to the practice of medical genetics.

<span class="mw-page-title-main">Myriad Genetics</span> American biotechnology company

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.

<span class="mw-page-title-main">Medical laboratory</span> Principles of management with special reference to medical science

A medical laboratory or clinical laboratory is a laboratory where tests are conducted out on clinical specimens to obtain information about the health of a patient to aid in diagnosis, treatment, and prevention of disease. Clinical medical laboratories are an example of applied science, as opposed to research laboratories that focus on basic science, such as found in some academic institutions.

The College of American Pathologists (CAP) is a member-based physician organization founded in 1946 comprising approximately 18,000 board-certified pathologists. It serves patients, pathologists, and the public by fostering and advocating best practices in pathology and laboratory medicine.

GeneDx is a genetic testing company that was founded in 2000 by two scientists from the National Institutes of Health (NIH), Sherri Bale and John Compton. They started the company to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which no such commercial testing was available at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, BioReference Laboratories acquired GeneDx. Since then, GeneDx has operated as a subsidiary of this parent company under the leadership of Bale and Compton. In October 2016, Benjamin D. Solomon was appointed as managing director.

The American Society for Investigative Pathology (ASIP) is a society of biomedical scientists who investigate mechanisms of disease. ASIP membership includes scientists in the academic, government, hospital, and pharmaceutical arenas that focus their research on the pathogenesis, classification, diagnosis and manifestations of disease. Research findings are ultimately used in the understanding, diagnosis and treatment of human diseases. The word pathology is derived from the Greek word "pathos" meaning "disease."

Mayo v. Prometheus, 566 U.S. 66 (2012), was a case decided by the Supreme Court of the United States that unanimously held that claims directed to a method of giving a drug to a patient, measuring metabolites of that drug, and with a known threshold for efficacy in mind, deciding whether to increase or decrease the dosage of the drug, were not patent-eligible subject matter.

A biological patent is a patent on an invention in the field of biology that by law allows the patent holder to exclude others from making, using, selling, or importing the protected invention for a limited period of time. The scope and reach of biological patents vary among jurisdictions, and may include biological technology and products, genetically modified organisms and genetic material. The applicability of patents to substances and processes wholly or partially natural in origin is a subject of debate.

<span class="mw-page-title-main">Molecular diagnostics</span> Collection of techniques used to analyze biological markers in the genome and proteome

Molecular diagnostics is a collection of techniques used to analyze biological markers in the genome and proteome, and how their cells express their genes as proteins, applying molecular biology to medical testing. In medicine the technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients, and in agricultural biosecurity similarly to monitor crop- and livestock disease, estimate risk, and decide what quarantine measures must be taken.

A variant of uncertainsignificance (VUS) is a genetic variant that has been identified through genetic testing but whose significance to the function or health of an organism is not known. Two related terms are "gene of uncertain significance" (GUS), which refers to a gene that has been identified through genome sequencing but whose connection to a human disease has not been established, and "insignificant mutation", referring to a gene variant that has no impact on the health or function of an organism. The term "variant' is favored in clinical practice over "mutation" because it can be used to describe an allele more precisely. When the variant has no impact on health, it is called a "benign variant". When it is associated with a disease, it is called a "pathogenic variant". A "pharmacogenomic variant" has an effect only when an individual takes a particular drug and therefore is neither benign nor pathogenic.

Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), was a Supreme Court case, which decided that "a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated.” However, as a "bizarre conciliatory prize" the Court allowed patenting of complementary DNA, which contains exactly the same protein-coding base pair sequence as the natural DNA, albeit with introns removed.

References

  1. ↑ "AMP Annual Reports". Association for Molecular Pathology. Retrieved 2023-02-16.
  2. 1 2 "AMP Education". educate.amp.org. Retrieved 2023-02-16.
  3. 1 2 "Special Articles". www.jmdjournal.org. Retrieved 2023-02-16.
  4. ↑ "Committees". Association for Molecular Pathology. Retrieved 2023-02-16.
  5. ↑ "Subdivisions". Association for Molecular Pathology. Retrieved 2023-02-16.
  6. ↑ "Past AMP Meetings". Association for Molecular Pathology. Retrieved 2023-02-16.
  7. ↑ "Molecular Medicine for Patients". AMP Out Reach. Retrieved 2023-02-16.
  8. ↑ "AMP Around the Globe". Association for Molecular Pathology. Retrieved 2023-02-16.
  9. ↑ Klein, Roger D. (2013-11-01). "AMP v Myriad: The Supreme Court Gives a Win to Personalized Medicine". The Journal of Molecular Diagnostics. 15 (6): 731–732. doi: 10.1016/j.jmoldx.2013.09.002 . ISSN   1525-1578. PMID   24139185.
  10. ↑ Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U. S. 576 (2013)
  11. ↑ "25 Years of Innovation". Association for Molecular Pathology. Retrieved 2023-02-16.
  12. ↑ "The Journal of Molecular Diagnostics". www.jmdjournal.org. Retrieved 2023-02-16.
  13. ↑ Bartley AN, Mills AM, Konnick E, et al. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med. 2022;146(10):1194-1210. doi:10.5858/arpa.2021-0632-CP
  14. ↑ "Corporate Support Opportunities". Association for Molecular Pathology. Retrieved 2023-02-16.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.